Dupilumab for cancer-associated refractory pruritus

Dupilumab for cancer-associated refractory pruritus

Background: Pruritus can be an intolerable symptom in patients with cancer. Type 2 inflammation, and specifically, the cytokines IL-4, IL-13, and IL-31, play major roles in the itching process. Dupilumab is an antibody against IL-4Rα, which is a common IL-4 and IL-13 receptor subunit. Blocking IL-4...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Aviv Talmon, MD, Shlomo Elias, MD, PhD, Limor Rubin, MD, Yaarit Ribak, MD, Eyal Ben Dori, MD, Oded Shamriz, MD, Michal Lotem, MD, Irit Adini, PhD, Yuval Tal, MD, PhD
Μορφή: Άρθρο
Γλώσσα:English
Έκδοση: Elsevier 2023-08-01
Σειρά:Journal of Allergy and Clinical Immunology: Global
Θέματα:
Oncologic pruritus
chronic pruritus
itch
IL-4
IL-13
IL-31
Διαθέσιμο Online:http://www.sciencedirect.com/science/article/pii/S277282932300053X

Διαδίκτυο

http://www.sciencedirect.com/science/article/pii/S277282932300053X

Παρόμοια τεκμήρια